During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma ...

Through continued collaborations with the Laboratory of Genetics in the Division of Basic Sciences and the Lymphoma Biology Section of the Division of Clinical Sciences, we are expanding this effort ...

which uses a small amount of radioactive dye to find areas of cancer There are a few subtypes of DLBCL. Each one has a different treatment and outcome. Primary mediastinal B-cell lymphoma starts ...

offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved hard to treat. First approved by the FDA in 2017, CAR T-cell therapy has the potential to cure your cancer. Here ...